CTOs on the Move

CSL Behring

www.cslbehring.com

 
Starting a century ago, CSL Behring made a promise to save lives and protect the health of people stricken with a range of serious and chronic medical conditions. Today that same promise has never been stronger. With operations in more than 30 nations and over 12,000 employees worldwide, we develop and deliver biotherapies to prevent and treat people with life-threatening medical conditions. Our broad-range of therapies include those to treat disorders such as hemophilia and primary immune deficiencies. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research. Our world-class commercial operation, ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Steven Yannelli
 Director of Application Security and Compliance Profile

Similar Companies

Robert E Mason Co

Robert E Mason Co is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Micron Technologies

Micron Technologies is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oratech

Oratech is a South Jordan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Foamix

Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology.

BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.